# Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

> **NCT02044380** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 14 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT02044380
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2017-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02044380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02044380, "Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02044380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*